GlassScriptPhysician profile
Kushal P Singh
NPI 1982876967
$4,029.19
in general payments reported to CMS, 2019-2025
38 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $526 · 2021: $727 · 2022: $654 · 2023: $649 · 2024: $469 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $668.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $365.76 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $309.96 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Horizon Therapeutics Plc | $262.59 | 2019-2022 | |
| Abbvie INC. | $225.28 | 2021-2024 | Ubrelvy |
| Glaxosmithkline, LLC. | $213.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $200.67 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $192.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.97 | 2021-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $175.85 | 2019-2025 | Verquvo |
| Shield Therapeutics INC | $165.54 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $123.26 | 2019-2022 | |
| Pfizer INC. | $114.12 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $106.13 | 2019-2024 | Airsupra, Farxiga |
| Daiichi Sankyo INC. | $72.68 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.91 | 2019-2020 | |
| Halozyme INC | $50.00 | 2023 | |
| Astellas Pharma US INC | $44.62 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $41.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.92 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $36.31 | 2021-2023 | Gvoke Hypopen |
| Abbott Laboratories | $34.38 | 2021 | |
| Ironwood Pharmaceuticals, INC | $32.26 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $31.91 | 2024-2025 | Voquezna |
| Globus Medical, INC. | $31.09 | 2025 | Senza |
| Dexcom, INC. | $29.00 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $27.24 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $25.40 | 2023 | Gemtesa |
| Insulet Corporation | $22.95 | 2023 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $21.81 | 2020 | |
| Mayne Pharma Commercial LLC | $19.59 | 2021 | |
| Corcept Therapeutics | $18.75 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $17.33 | 2021 | |
| Esperion Therapeutics, INC. | $16.02 | 2021 | |
| Melinta Therapeutics, LLC | $14.86 | 2019 | |
| Abiomed | $14.79 | 2024 | Impella |
| Radius Health, INC. | $14.35 | 2021 | |
| Amarin Pharma, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kushal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.